)
)
Nanexa Investor Relations Material
Latest events
Study Result
Nanexa
Access the full event backlog
Slides, Transcripts, and Reports from 12,000+ public companies
Latest reports from Nanexa
Access all reports
Nanexa AB focuses on developing nanoparticle technology for drug delivery. The company utilizes their proprietary NxCore platform to transform drugs from conventional to nanomedicines. Their lead product candidate is Nanoxel, a nanomedicine that targets oral mucositis, a common and exceptionally debilitating side effect in cancer patients receiving chemotherapy and radiation therapies; and angina pectoris and heart failure caused by atherosclerosis, a build-up of plaque in the blood vessels. The company intends to transform new products into nanomedicines or develop completely new nanomedicines.
Latest articles
)
Quartr Brings Stories Behind the Numbers to Light
Quartr simplifies access to IR material and puts qualitative insights and company narratives front and center.
3 Feb 2025
)
The Evolution of the IRO Role: Staying Informed and Strategic With Quartr Pro
Staying informed is critical for IROs. Quartr Pro simplifies gathering market insights and narrative positioning with unprecedented speed and precision.
3 Feb 2025
)
Mips: The Gore-Tex of Brain Protection
How Mips turned a critical safety flaw into a global success, redefining helmet protection with its technology and ingredient brand business model.
24 Jan 2025
Ticker symbol
NANEXA
Country
🇸🇪 Sweden